The Problem
The Solution
The Impact
Conventional therapeutics face significant delivery hurdles, leading to high manufacturing costs, massive CO2 emissions, and inconsistent patient adherence that limits global health impact.
Our synthetic gene platforms transform the body into a localized bio-factory. By delivering 'plug and play' genetic blueprints, we enable cells to manufacture precisely targeted treatments from within.
This paradigm shift eliminates complex chemical manufacturing, drastically reduces healthcare costs, and slashes the carbon footprint of medicine while ensuring equitable access to life-saving preventions or treatments.
The Problem
Fragmented manufacturing and high-dose requirements in medicine lead to immense economic costs and millions of tons of CO2 emissions annually.
Our Solution
Proprietary synthetic gene platforms that act as 'plug and play' biocatalysts, engineering therapeutics directly within the patient's own cells.
The Impact
Reducing doses and eliminating external production support equitable access, save millions for health systems, and drastically cut the ecological footprint.
Born from Global Innovation
Pioneering research from King’s College London turned into industrial reality. We transform intellectual rigor into agile biotech solutions, engineering bespoke gene platforms that redefine the boundaries of preventive medicine and sustainable therapeutics.